Palmetto Retina Center
Florence, South Carolina 29501
1 studies enrolling now · 14 studies all time
What they study most
Age-Related Macular Degeneration, Choroidal Neovascularization, Diabetic Macular Edema, Geographic Atrophy, Macular Degeneration, Neovascular Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Retinal Neovascularization, Wet Age Related Macular Degeneration, Wet Macular Degeneration, wAMD
Studies at this site
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) — Recruiting now
- Extension Study for the Port Delivery System With Ranibizumab (Portal) — Recruiting now
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) — Recruiting now
- A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 — Running, not enrolling
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration — Running, not enrolling
- A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. — Stopped early
- Home OCT Guided Management Study of Subjects Diagnosed With Neovascular-AMD — Status unconfirmed
- A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration — Completed
- Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration — Completed
- A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema — Completed
- A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
- A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
- A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
- Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) — Stopped early